(VIR) Vir Biotechnology, Inc. Business Model Canvas Research

Vir Biotechnology, Inc.'s collaboration and license with Alnylam Pharmaceuticals adds RNAi to a company built around antibodies, so the technology base is broader and less single-platform. The deal supports combo or adjacent approaches in infectious disease, where RNAi can be paired with Vir's immune-targeted programs to hit the same pathogen from two angles.

• RNAi expands Vir Biotechnology, Inc.'s toolset beyond antibodies
• Supports combo and adjacent therapeutic strategies
• Improves platform breadth for infectious-disease programs

Vir Biotechnology, Inc. groups these partners across development, manufacturing, and IP: Gilead backs chronic hepatitis B work, while Samsung Biologics adds large-scale biologics capacity. WuXi Biologics, GSK Biologicals, Rockefeller University, and MedImmune deepen R&D, collaboration, and licensed IP access.

• Gilead: hepatitis B development
• Samsung Biologics: manufacturing capacity
• WuXi, GSK, Rockefeller, MedImmune: research and IP

Vir Biotechnology coordinates external manufacturing of antibody supply with partners such as Samsung Biologics, using large-scale GMP capacity to keep output quality-controlled and scalable. Samsung Biologics reports 784,000 L of total biomanufacturing capacity, which helps reduce supply bottlenecks for clinical and commercial needs.

• Outsourced GMP antibody production
• Samsung Biologics as key partner
• Scalable, quality-controlled supply

Vir Biotechnology, Inc. runs partnership and license management as a core activity, handling grants, options, collaborations, and licenses with multiple counterparties. That fits its alliance-heavy model: it speeds development, spreads cost and risk, and limits internal buildout while keeping access to external science and rights.

• Manages many counterparties
• Supports faster development
• Reduces internal buildout
• Protects access to key rights

Vir Biotechnology, Inc. relies on licensed IP and option rights from Brii Biosciences, Alnylam, Rockefeller University, and MedImmune to advance programs without owning every core invention. That lowers upfront R&D load and can shorten the path to clinic, which matters in a 2025 market where time and capital are tight.

• Four key partner sources
• Less upfront invention risk
• Faster program entry

Vir Biotechnology, Inc.’s partner network is a core resource because biotech value often comes from shared R&D, manufacturing, and commercialization know-how, not just in-house IP. Its San Francisco headquarters keeps the Company close to a top talent pool, venture capital, and the Bay Area biotech cluster, where over 1,000 life-science firms operate.

• Partner network drives scientific scale
• San Francisco supports talent access
• Hub location helps investor reach

VIR-1111 is a prevention-focused HIV asset that fits Vir Biotechnology, Inc.’s immunology-led strategy. The addressable need is large: UNAIDS estimated 39.9 million people living with HIV and 1.3 million new infections in 2023, so a durable prevention option could target a major global burden.

• Prevention-first HIV asset
• Targets a 39.9 million patient burden
• Supports Vir Biotechnology, Inc. immunology strategy

Vir Biotechnology, Inc. pairs internal science with external partners for funding, licensing, and manufacturing, which cuts capital needs and speeds execution. That matters for stakeholders: Vir ended FY2024 with about $1.0 billion in cash, cash equivalents, and investments, showing how partner-led development can preserve balance-sheet strength.

• Less capital tied up in plants
• Faster path to clinic and market
• Shared funding and manufacturing risk

Vir’s regulatory and medical affairs team stays in active contact with regulators, healthcare professionals, and evidence users to support safety, proper use, and market trust for infectious-disease products. This matters because even one label update or safety signal can affect adoption, and medical affairs now has to back decisions with fresh clinical and real-world data.

• Supports safe, approved use
• Keeps regulators aligned
• Builds clinician confidence
• Strengthens evidence-based uptake

Vir Biotechnology, Inc. runs license and supply agreements through formal, contract-heavy controls with licensors, manufacturers, and development partners. This keeps IP rights, GMP supply, and joint development terms aligned, which matters when collaboration revenue and R&D spend depend on clean milestone and compliance tracking.

• Licensors: protect IP rights.
• Manufacturers: secure compliant supply.
• Partners: track milestones and duties.

Vir Biotechnology, Inc. uses healthcare and public-health distribution to reach hospitals, clinics, and government buyers for infectious-disease products, which is the key route for commercial and emergency-response use. This channel matters most when speed, cold-chain handling, and public procurement decide access; WHO still estimates antimicrobial resistance drives about 1.27 million deaths a year.

• Hospitals and clinics drive bedside use.
• Government buyers support outbreak response.
• Public-health channels speed real deployment.

Scientific and regulatory submissions are a core channel for Vir Biotechnology, Inc. because filings, investor presentations, and agency review packages move candidates through FDA and other oversight steps toward approval and use. Vir remained clinical-stage in 2025, so these submissions are the bridge between trial data and market adoption.

• Supports FDA and global review
• Converts data into approval files
• Needed in regulated biopharma markets

Pharma and biotech partners are Vir Biotechnology, Inc.’s core B2B customers: they license, co-develop, and may manufacture programs, so they bring cash, scientific know-how, and commercial reach. This model is visible in Vir’s GSK and Alnylam collaborations, which extend Vir’s pipeline without building every capability in-house.

• License and co-dev programs
• Provide capital and scale

Research institutions and funders include universities, nonprofits, and public bodies that back infectious-disease science. NIH alone had about $48.6 billion in FY2024 funding, and those grants support discovery, validation, and translational work that can de-risk Vir Biotechnology, Inc. programs.

• Universities drive early discovery
• Nonprofits fund disease-specific work
• Public bodies support translation

Vir Biotechnology does not separately disclose regulatory, legal, and IP spend; those costs sit inside G&A and program support, covering filings, compliance, license upkeep, and patent prosecution. In a collaboration-led model, that spend protects commercialization rights and helps defend program value across partnered assets.

• Filing and compliance costs
• License and patent upkeep
• Protects commercialization rights
• Supports partnered programs

Vir Biotechnology, Inc. uses selling, general, and administrative costs for corporate overhead, partnership management, and commercial support from its San Francisco headquarters. In FY2025, this line funded the business side of a science-led company, including legal, finance, people, and partner-facing work that keeps programs moving.

• San Francisco HQ overhead
• Partnership management support
• Commercial and admin functions

Royalty income is a contingent upside for Vir Biotechnology, Inc.: if a partner-developed product reaches commercialization under license terms, Vir Biotechnology can earn a share of sales with little extra cost. In licensing-heavy models, that makes royalties a high-margin stream that rewards successful externalized development.

• Paid only after partner commercialization

• High-margin, low incremental cost

• Depends on partner sales and terms

Vir Biotechnology, Inc. uses grant funding from groups like the Gates Foundation and the NIH as non-dilutive cash for early research. It is not product revenue, but it helps pay for high-risk programs and lowers the need to issue new shares.

• Non-dilutive research cash
• Supports early-stage work
• Backed by NIH and Gates